Bisphosphonates have been widely used in the treatment of osteoporosis with robust data from numerous placebo-controlled trials demonstrating efficacy in fracture risk reduction over 3-5 years of treatment. Although bisphosphonates are generally safe and well tolerated, concerns have emerged about adverse effects related to long-term use. For most patients with osteoporosis, the benefits of treatment outweigh the risks. Because these agents accumulate in bone with some persistent antifracture efficacy after therapy is stopped, it is reasonable to consider a 'drug holiday.' There is considerable controversy regarding the optimal duration of therapy and the length of the holiday, both of which should be based on individual assessments of risk and benefit.
Introduction
Bisphosphonates are widely prescribed for the treatment of osteoporosis. These popular and effec tive agents have a high affinity for bone and reduce bone resorption by causing loss of osteoclastic resorptive function as well as accelerating osteo clast apoptosis by inhibiting farnesyl pyrophos phate synthase, an enzyme in the HMGCoA reductase pathway. The four nitrogencontaining bisphosphonates currently in clinical use for the treatment of osteoporosis differ in the strength for binding to bone. The rank order for binding affin ity is zoledronate > alendronate > ibandronate > risedronate [Russell et al. 2008] . Higheraffinity bisphosphonates will bind avidly to the bone sur face but will spread through bone more slowly, while loweraffinity agents will be distributed more widely through the bone but have a shorter resi dence time in bone if treatment is stopped. These agents also differ in the potency for inhibiting farnesyl pyrophosphate synthase. The rank order of potency for inhibiting this enzyme is zoledro nate > risedronate >> ibandronate > alendronate [Russell et al. 2008] . Bisphosphonate use results in a rapid and substantial decrease in bone turnover markers that is dose and compound dependent, with a maximum effect in 3-6 months. This effect is maintained in a new steady state for at least 10 years with continued treatment [Bone et al. 2004] . Therefore, each bisphosphonate has a unique profile of binding affinity and antiresorptive potency that likely result in clinically meaningful differences in the degree of reduction of bone turnover and the speed of onset and offset of effect.
The skeletal binding sites for bisphosphonates are virtually unsaturable, so a substantial amount could be accumulated over time, leading to a res ervoir that continues to be released for months or years after treatment is stopped [Papapoulos and Cremers, 2007] . Since release depends in part on the level of bone turnover, which is reduced by the presence of bisphosphonates, the actual amount released may be fairly small. For exam ple, the amount of alendronate released from bone over the next several months or years after a 10year treatment period with alendronate would be equivalent to taking one quarter of the usual dose [Rodan et al. 2004] . When treatment is stopped, if there is continued presence of bis phosphonate in bone and continued release (and possible reattachment to bone), there might be some lingering antifracture effect after treatment is stopped. This is why it is reasonable to con sider a 'drug holiday' from bisphosphonate ther apy, a period of time when treatment is stopped after continuous treatment. However, the term Bisphosphonate drug holiday: who, when and how long 'holiday' implies that treatment will be restarted after some time off.
Studies of long-term use of bisphosphonates
Approval of bisphosphonates in the US was based on studies of 3-4 years duration, although some of these studies have been extended, with alendronate, risedronate and zoledronic acid suggesting efficacy for up to 10 years [Black et al. 2006; Schwartz et al. 2010] , 7 years [Mellstrom et al. 2004] , and 6 years [Black et al. 2012b ], respectively.
The extension of the alendronate Fracture Intervention Trial (FLEX) enrolled subjects who had approximately 5 years of alendronate treat ment in the FLEX study into a second 5year study where subjects were randomized to either continue alendronate or start placebo. At the end of the FLEX study, spine bone mineral density (BMD) increased more (+3.8%) in the longterm treated groups as opposed to the placebo group. Discontinuation of alendronate was associated with gradual increases of bone turnover markers, although at the end of 5 years after stopping alendronate, levels remained somewhat below pretreatment levels 10 years earlier. There were fewer clinical vertebral fractures in the longterm treated group (55% reduction) that met statistical difference from the placebo group (~2% versus 5%, relative risk (RR) 0.45, p = 0.013) [Black et al. 2006] . A post hoc analysis of the FLEX data indicated that nonvertebral fracture risk reduc tion was also observed in the subset of patients without prior vertebral compression fractures but only in those with Tscores entering FLEX of -2.5 or lower at the femoral neck hip [Schwartz et al. 2010 ].
The extension of the risedronate VERTNA study was a 1year follow up of subjects who completed 3 years of blinded therapy with risedronate or placebo, then stopped their study medications. In the year off treatment, BMD decreased in the for mer risedronate users, but remained higher than baseline and higher than in the former placebo subjects. Furthermore, bone turnover markers increased and were no different from the former placebo subjects. Despite the apparent resolution of treatment effect on these markers, the risk of new vertebral fractures was reduced by 46% in the former risedronate users compared with the former placebo subjects . Similarly, a recent study looking at the effect of discontinuing risedronate for 1 year after 2 or 7 years of treatment also showed decreasing BMD in the total hip and trochanter regions as well as increasing bone turnover markers [Eastell et al. 2011 ].
In the 3year extension of the zoledronate HORIZON pivotal fracture trial, subjects who received three doses of zoledronate in the pla cebocontrolled were assigned at random to one of two arms: a continuation group that received 6 years of zoledronic acid administration and a discontinuation group that received the initial 3 years of zoledronic acid then went to placebo [Black et al. 2012b ]. There were small differences in bone density and bone turnover markers in those who continued versus those who stopped treatment, suggesting residual effects. However, there were significantly fewer morphometric vertebral fractures in the group that continued treatment compared with the placebo group (14 versus 30, odds ratio [OR] 0.51, 95% confidence interval [CI] 0.26-0.95, p = 0.035), suggesting that patients at high fracture risk may benefit from continued treatment. Since the majority of subjects in the HORIZON registration trial had prevalent vertebral fractures, the continuation efficacy is most likely confined to those higher risk patients with vertebral compression fractures [Black et al. 2012b ].
In terms of longterm safety of bisphosphonate use, concerns about two uncommon but possi ble timerelated adverse events have emerged: osteonecrosis of the jaw (ONJ) and atypical femur fractures (AFFs). Although no specific issues were identified in the abovementioned studies, recent evidence supports an association between prolonged bisphosphonate exposure and these two serious conditions. In a retrospec tive review of the HORIZON trial with intrave nous (IV) zoledronate for osteoporosis [Grbic et al. 2010] , one case of ONJ was reported in the treatment group and another in the placebo group. A total of 12 fractures in 10 women were classified as subtrochanteric in secondary analy ses of the FIT, FLEX and HORIZON Pivotal Fracture Trials, indicating that the risk of such fractures with use of bisphosphonates was very low, even in women who received bisphospho nates for up to 10 years ]. Furthermore, iliac crest biopsies after up to 10 years of treatment have not shown oversuppres sion of bone turnover. Importantly, no causal relationship has been established between prolonged bisphosphonate exposure and either of these outcomes. Even though the risks of ONJ and AFF may increase after 5 years of bisphos phonate therapy, the likelihood remains low. Nevertheless, these safety concerns have led to considerable debate about how long to treat with bisphosphonates.
Drug holidays
On 9 September 2011, the US Food and Drug Administration (FDA) held a hearing to review the longterm safety and efficacy of bisphos phonates including alendronate, risedronate, ibandronate and zoledronate. The majority of the advisory committee (17 to 6) voted that labeling for these drugs should further clarify the duration of use for bisphosphonates but there was a lack of panel consensus on label changes. The FDA wrote their opinion on this perspective, suggesting reevaluation of the need for continuing bisphosphonate therapy beyond 3-5 years in individual patients [Whitaker et al. 2012 ]. The FDA suggested that a drug holiday may not be advisable in highrisk patients, but for patients discontinuing treatment, there were no concrete recommendations on what should be done.
Subsequently, there has been considerable dis cussion about who benefits from a drug holiday, when to initiate it, and the ideal duration of the holiday. It is important to note that data from the clinical trials discussed above suggest that the risk of vertebral fractures is reduced beyond 5 years of therapy. In FLEX, the number needed to treat (NNT) for 5 years to prevent one clinical vertebral fracture was 17 in women with a preva lent vertebral fracture and a femoral neck Tscore of -2.0 or below at the start of the extension trial, and 24 for women without vertebral fracture and a femoral neck Tscore of -2.5 or below [Black et al. 2012a ]. Hence, there is evidence for benefit with continued therapy through 10 years in this subset of patients. The 10year fracture risk assessments with the fracture risk assessment system (FRAX) are increasingly used to guide treatment decisions. A recent study by Leslie and colleagues suggested that the FRAX tool can be used to predict fracture probability in women currently or previously treated for osteoporosis, which may help in guiding the need for contin ued treatment or treatment withdrawal [Leslie et al. 2012] .
Therefore, although there is some residual bene fit in terms of fracture reduction for some time after a 3 to 5year course of bisphosphonate therapy, continuing treatment for 10 years seems to be a better choice for highrisk patients. Even though the risks of bisphosphonate therapy for osteoporosis are small, the risk/benefit ratio may be harmful for lowrisk patients. For patients who were candidates for treatment, treatment may be stopped for a drug holiday after a course of some years.
At present, it is difficult to find evidence to sup port the need for a drug holiday or to establish the effectiveness of treatment after restarting therapy. Similarly, there is no strong evidence to provide guidance in terms of how long to treat, how long the holiday should be, and when the holiday should be stopped. Nevertheless, we believe there is logic to support the following clinical scenarios [Diab and Watts, 2012; Watts and Diab, 2010] .
1. Low risk of fracture: treatment is not needed. If a bisphosphonate has been pre scribed, it should be discontinued and not restarted unless/until the patient meets treatment guidelines. Example: 54year old woman, menopause at age 51, lowest Tscore -1.5, no risk factors, bisphospho nate therapy for 3 years. Treatment was not indicated in the first place and can be discontinued. 2. Mild risk of fracture: treat with bisphos phonate for 3-5 years, then stop. The 'drug holiday' can be continued until there is significant loss of BMD (i.e. more than the least significant change as determined by the testing center) or the patient has a fracture, whichever comes first. Example: 68yearold woman, menopause at age 50, initial lowest Tscore -2.3, parent with a hip fracture, bisphosphonate treatment for 5 years, BMD stable over that time. Treatment was indicated, but a drug holi day might be considered after 5 years of treatment. 3. Moderate risk of fracture: treat with bis phosphonate for 5-10 years, offer a 'drug holiday' of 3-5 years or until there is signifi cant loss of BMD or the patient has a fracture, whichever comes first. Example: 72yearold woman, menopause at age 48, lowest initial Tscore -2.8, no risk factors, bisphosphonate therapy for 7 years, BMD increased over that time so lowest Tscore now is -2.3. Treatment was indicated but after 7 years of treatment, a drug holiday might be considered. 4. High risk of fracture (fractures, corticos teroid therapy, very low BMD): treat with bisphosphonate for 10 years, offer a 'drug holiday' of 1-2 years, until there is signifi cant loss of BMD or the patient has a fracture, whichever comes first. A nonbis phosphonate treatment (e.g. raloxifene or teriparatide) may be offered during the 'holiday' from the bisphosphonate. Example: 75yearold woman, menopause at age 45, lowest initial Tscore -3.6, rheumatoid arthritis requiring ongoing corticosteroid therapy for 12 years, two vertebral fractures by vertebral fracture assessment (VFA), treatment with bisphosphonate therapy for 10 years. Treatment was indicated and she remains at high risk of fracture after 10 years. If a holiday from the bisphosphonate is considered, interval treatment with teri paratide or raloxifene would be prudent.
If a drug holiday is advised, reassessment of risk should occur sooner for drugs with lower skeletal affinity, with a suggestion to reassess after 1 year for risedronate, 1-2 years for alendronate, and 2-3 years for zoledronic acid [Compston and Bilezikian, 2012] . Although it has been proposed that a decrease in BMD or an increase in bone turnover marker (BTM) might be used to decide when to end a drug holiday, there is lack of data on risk for fracture when these surrogate markers begin to change off bisphosphonates. The risedro nate study showed that fracture risk remained reduced despite what appeared to be unfavorable changes in these parameters. Conversely, there is no evidence that fracture risk is reduced if BMD is stable or BTM is low off treatment. That being said, in clinical practice, monitoring BMD and BTM are the only means of gaining some sense of the loss of the effect of the bisphosphonate on bone remodeling, but ultimately the duration of the holiday should be based on clinical judgment.
Conclusion
In conclusion, bisphosphonates that have been approved for the treatment of postmenopausal osteoporosis are effective and generally safe agents that have robust evidence for fracture risk reduction. Their systemic safety is related to their binding to bone and lack of uptake by other tis sues other than the kidney. A reservoir of bispho sphonates accumulates after years of treatment that is gradually released over months or years and appears to result in a lingering antifracture benefit for some time after therapy is stopped. This makes it possible to consider 'drug holidays', time off bisphosphonate therapy (but possibly on another agent), and then resuming therapy. Although there is no strong evidence to guide us, we believe that some time off treatment should be offered to most patients on longterm bisphos phonate therapy. The duration of treatment and the length of the 'holiday' should be tailored to individual patient circumstances and based on individual assessments of risk and benefit. In the higherrisk population treated for the right dura tion, bisphosphonates have an exceptionally high benefit/risk ratio. While lowerrisk patients may be offered a 'drug holiday' after 3-5 years of use, higherrisk patients should be counseled on the greater risk for fracture if discontinuation is initi ated. The strength of the evidence for fracture reduction in highrisk individuals and the rarity of longterm adverse effects indicate that the bene fits of continued treatment outweigh the risks in individuals at high risk of fracture.
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